73rd ASMS Conference on Mass Spectrometry and Allied Topics – Waters Corporation (NYSE:WAT) today announced the launch of the Xevo™ TQ Absolute XR Mass Spectrometer, the Company’s most sensitive, robust, and reliable benchtop tandem quadrupole.
Notably, the product exceeds the performance capabilities of the Xevo TQ Absolute, which itself set the benchmark in the industry for tandem quadrupole sensitivity, particularly in areas such as pharmaceutical quantitation and PFAS detection. Tailored for high-throughput applications in pharmaceutical companies, contract testing organizations, and government laboratories, the new system is designed to deliver exceptional performance for the most sensitive trace-level analyses in complex matrices, while maximizing system uptime and efficiency.
“Analytical laboratories are under pressure to adapt to the complex needs of pharmaceutical organizations, and meet the increasing demand for PFAS testing driven by a rapidly evolving regulatory landscape,” said James Hallam, Vice President, Liquid Chromatography-Mass Spectrometry, Waters Corporation. “The Xevo TQ Absolute XR design delivers up to a six-fold increase in performance robustness with unmatched sensitivity and resilience to contamination, significantly reducing downtime and enhancing operational efficiency for our customers.”
Built on the trusted, intuitive design of the Xevo TQ Absolute Mass Spectrometer, the Xevo TQ Absolute XR Mass Spectrometer offers significant operational efficiencies. It uses up to 50% less power and nitrogen gas, produces 50% less heat than any other high-performing tandem or triple quadrupole on the market, and takes up to 50% less bench space, making it the ideal system for laboratories striving to reduce their environmental footprint without compromising throughput or performance.
Within the Xevo TQ Absolute XR Mass Spectrometer, Waters introduces the StepWave XR Ion Guide, which incorporates sophisticated technology designed to minimize the risk of unplanned downtime, while preserving high sensitivity and precision for even the most complex sample types and fragile compounds. Through this innovation, customers are realizing a new benchmark of robustness across a wide range of applications, including PFAS, bioanalysis, and genotoxic impurity testing.
“Our laboratory requires instrumentation that delivers high-quality, interruption-free results to our customers, helping them to bring safe and effective new drugs to market with confidence and speed,” said Sally Hannam, Scientific Director, Synexa Life Sciences, a leading biomarker and bioanalytical services provider. “We are well in excess of 20,000 injections of crashed human plasma continuously analyzed on the Xevo TQ Absolute XR Mass Spectrometer combined with the ACQUITY™ Premier UPLC™ System and waters_connect™ Software, and our early experience is that it demonstrates new levels of reproducibility and accuracy, giving us ever more confidence as we are presented with increasingly challenging bioanalysis applications and new modalities.”
In addition, the design of the Xevo TQ Absolute XR Mass Spectrometer delivers industry-leading, out-of-the-box quantitation of negatively ionizing compounds, such as PFAS. Bioanalytical, food safety, and environmental testing laboratories will benefit from the high confidence results and operational efficiency gains that the Xevo TQ Absolute XR Mass Spectrometer delivers.
The Xevo TQ Absolute XR Mass Spectrometer is available to order now.
